New drug cocktail takes on deadly brain cancer
NCT ID NCT07391215
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new drug called paxalisib combined with standard chemotherapy (temozolomide) in people with high-grade brain tumours like glioblastoma. The goal is to find a safe dose and see if the combination can slow tumour growth. About 64 participants will be enrolled, and the trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paxalisib (a targeted drug) combined with temozolomide (chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with aggressive brain tumours, potentially slowing disease progression.
What could go wrong
This is an early-phase trial with only 64 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Marden NHS Foundation Trust
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••